Chronic Myeloid Leukemia

also called: Chronic Myelogeneous LeukemiaA chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

Philadelphia chromosome

A certain change in chromosomes (on chromosome 22) found in 95% of patients who have CML. The Philadelphia chromosome results from a mutation that involves the fusion of parts of chromosome 9 and chromosome 22 (the bcr-abl fusion gene)

Maintenance therapy

Treatment (e.g. chemotherapy) that is usually given for a long time to stabilize the success of induction or consolidation therapy.

Inclusion criteria

Inlusion criteria define which subjects may participate in a clinical study. Study subjects must fulfill all inclusion criteria (e.g. with regard to sex, age, previous diseases). This ensures a uniform composition of the study population and minimizes the risk of influences that distort the study results.

Chronic phase

The earliest phase of CML development.

Chromosome

A chromosome is a structure of DNA that carries the genetic makeup in the nucleus of the cell. Chromosomes contain giant chain molecules of DNA, coiled and folded as aggregates with specific proteins. Chromosomes ensure that during cell division the hereditary information is evenly distributed to the daughter cells. Normal human body cells have 46 chromosomes. Cancer cells can have a different number and/or structure of chromosomes.

Indication

In medicine, a reason to use a certain diagnostic test, therapeutic procedure or medication. The opposite of indication is contraindication.

Nilotinib

Trade name: Tasigna, development name: AMN107, inhibits BCR-ABL tyrosine kinase. Authorized for marketing in the EU since 2007 for the treatment of CML and Ph+ALL.Other names: |AMN107|Tasigna

Protocol

The action plan for the research work, which explains key objectives and procedures. In case of a clinical trial, the protocol defines e.g. the purpose of the study, how many people will participate, eligibility criteria, the medical intervention, etc.

Imatinib

Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.Other names: Gleevec|Glivec

BCR-ABL

The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22

Chronic

Long-lasting, slowly developping

Gene

A unit of information present as DNA; a gene usually contains the blueprint for a protein.

CML

Chronic Myeloid Leukemia, also called Chronic Myelogenous LeukemiaA chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

CHR

Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

Short description of intervention

Attempt of CML treatment optimization. There will be two groups in this study: one group will receive nilotinib alone, the other group will receive a combination of nilotinib and interferon alpha. During a later treatment phase, nilotinib or interferon alpha will be given as maintenance therapy, and discontinued if MR improves further for at least 12 months.

Chronic Myeloid Leukemia

also called: Chronic Myelogeneous LeukemiaA chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

Philadelphia chromosome

A certain change in chromosomes (on chromosome 22) found in 95% of patients who have CML. The Philadelphia chromosome results from a mutation that involves the fusion of parts of chromosome 9 and chromosome 22 (the bcr-abl fusion gene)

Maintenance therapy

Treatment (e.g. chemotherapy) that is usually given for a long time to stabilize the success of induction or consolidation therapy.

Inclusion criteria

Inlusion criteria define which subjects may participate in a clinical study. Study subjects must fulfill all inclusion criteria (e.g. with regard to sex, age, previous diseases). This ensures a uniform composition of the study population and minimizes the risk of influences that distort the study results.

Chronic phase

The earliest phase of CML development.

Chromosome

A chromosome is a structure of DNA that carries the genetic makeup in the nucleus of the cell. Chromosomes contain giant chain molecules of DNA, coiled and folded as aggregates with specific proteins. Chromosomes ensure that during cell division the hereditary information is evenly distributed to the daughter cells. Normal human body cells have 46 chromosomes. Cancer cells can have a different number and/or structure of chromosomes.

Indication

In medicine, a reason to use a certain diagnostic test, therapeutic procedure or medication. The opposite of indication is contraindication.

Nilotinib

Trade name: Tasigna, development name: AMN107, inhibits BCR-ABL tyrosine kinase. Authorized for marketing in the EU since 2007 for the treatment of CML and Ph+ALL.Other names: |AMN107|Tasigna

Protocol

The action plan for the research work, which explains key objectives and procedures. In case of a clinical trial, the protocol defines e.g. the purpose of the study, how many people will participate, eligibility criteria, the medical intervention, etc.

Imatinib

Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.Other names: Gleevec|Glivec

BCR-ABL

The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22

Chronic

Long-lasting, slowly developping

Gene

A unit of information present as DNA; a gene usually contains the blueprint for a protein.

CML

Chronic Myeloid Leukemia, also called Chronic Myelogenous LeukemiaA chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

CHR

Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

GUS

ß-glucuronidase; an enzyme

CAM

Complementary and Alternative Medicine

0

Please leave your blog comments on the above article here. Your comment will be checked by the website team. When approved, it will appear here on this website.